Please type a plus sign (+) inside this box [+]

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPE JAN 28 2004 PATENT & TRADEMARK OFFICE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	10/679,257
Filing Date	October 7, 2003
First Named Inventor	Loscalzo
Group Art Unit	1655
Examiner Name	Dr. K.C. Srivastava
Attorney Docket Number	102258.337 US2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
KS		Johnson, Clinical Pharmacy, Vol. 5, pages 536 and 541 (1986).	
KS		Massie et al, Br. Heart J., 45:376-384 (1981).	
KS		Turner et al, The American Journal of Cardiology, 47:910-916 (1981).	
KS		Massie et al, Circulation, 63(3):658-664 (1981).	
KS		Nelson et al, Journal of Cardiovascular Pharmacology, 5(4):574-579 (1983).	
KS		Leier et al, Circulation, 63(1):102-109 (1981).	
KS		Wilson et al, The American Journal of Medicine, 71:627-633 (1981).	
KS		Biddle et al, J. Clin. Pharmacol., 21:343-350 (1981).	
KS		Magorien et al, ~~Midwest Cardiovascular, page 617A~~ Clinical Research 27(4) A617 (1979).	
KS		Turner et al, Clinical Research, 29(2):246A (1981).	
KS		Hibiya et al, Japanese Circulation Journal, 45:966 (Abstract No. 338) (1981).	

Examiner Signature	/Kailash Srivastava/	Date Considered	07/09/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

Complete If Known	
Application Number	10/679,257
Filing Date	10/07/2003
First Named Inventor	LOSCALZO, et al.
Art Unit	~~1615~~ 1655
Examiner Name	~~To Be Assigned~~
Attorney Docket Number	102258.337US2

EXAMINER: Dr. K.C.Srivastava

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
KS	AK	KAHN, Jonathan, "How a Drug Becomes "Ethnic": Law, Commerce, and the Production of Racial Categories in Medicine," Yale Journal of Heath Policy, Law, and Ethics IV:1 (2004), pp. 1-46	
KS	AL	PARKER, John D., et al., "The Effect of Hydralazine on the Development of Tolerance to Continuous Nitroglycerin," The Journal of Pharmacology and Experimental Therapeutics, Vol. 280, No. 2, pp. 866-875 1997.	
KS	AM	KALINOWSKI, Leszek, et al., "Race-Specific Differences in Endothelial Function - Predisposition of African Americans to Vascular Diseases," Circulation, June 1, 2004, pp. 2511-2517	

Examiner Signature	/Kailash Srivastava/	Date Considered	07/09/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.